William Moore Appointed as Cerus Corporation's Senior Vice President of Manufacturing Operations and Supply Chain

Cerus Corporation CERS announced today the appointment of William Moore to the newly created position of Senior Vice President of Manufacturing Operations and Supply Chain for Cerus, effective January 1, 2019. Mr. Moore joins Cerus from Quest Diagnostics, where he served as Vice President, Lab Operations and was previously the Senior Vice President of Operations, Biomedical Services at the American Red Cross, the world's largest blood center operation.

"As Cerus' global operations scale with the increasing adoption of INTERCEPT worldwide, we are excited to announce the addition of Bill Moore to our senior management team," said William 'Obi' Greenman, president and chief executive officer of Cerus. "Bill's extensive experience in manufacturing operations and his understanding of blood center operations gained from his decade at the American Red Cross will provide Cerus with the critical capabilities needed to meet the important requirements of our blood center customers. His experience and expertise will be invaluable, especially in light of our anticipated business growth and as the INTERCEPT technology becomes increasingly integral to blood center operations worldwide."

"The focus of my career has been to optimize operations and to achieve maximum efficiency from manufacturing operations and supply chains, always with patient safety at the forefront," Moore said. "With the increasing demands on Cerus for production capacity and supply chain security, I am excited to help Cerus scale its business. In particular, I look forward to working with Cerus' suppliers and customers on the planned INTERCEPT red cell launch in Europe. My past experience at the American Red Cross is particularly relevant for the possible production demands associated with the expected INTERCEPT Cryoprecipitate launch in the U.S."

The appointment of Mr. Moore, following the recent CE Mark submission of the INTERCEPT Blood System for red cells and the Breakthrough Device Designation for INTERCEPT Cryoprecipitate, underscores Cerus' dedication to its important mission to help protect the safety of the blood supply in the United States and globally.

Mr. Moore most recently served as Vice President, Lab Operations at Quest Diagnostics, where he was responsible for approximately 1,700 employees in all laboratory operations across Quest Diagnostics' East Region with annual revenue of approximately $1.5 billion. Prior to that, he served as Senior Vice President, Operations, Biomedical Services at the American Red Cross, where, as the senior operations executive in the world's largest blood banking operation, he was responsible for over 5,000 employees and an annual operating budget of $800 million. Bill's 11-year tenure at the Red Cross included national responsibility for all testing laboratories, donor health, customer service and manufacturing operations. He led the integrated supply chain including technical procurement, fleet, warehousing, kitting, logistics, and distribution.

Prior to joining Red Cross, Bill spent more than 20 years in the specialty chemicals industry with American Cyanamid Company and Cytec Industries, holding leadership roles in engineering, global supply chain, manufacturing, R&D and quality. Bill holds a B.Engr. in Chemical Engineering from The Cooper Union (NYC) and an M.B.A. in General Management/Corporate Strategy from New York University.

ABOUT CERUS

Cerus Corporation is a biomedical products company focused in the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action of the INTERCEPT treatment is designed to inactivate established transfusion threats, such as hepatitis B and C, HIV, West Nile virus and bacteria, as well as emerging pathogens such as chikungunya, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in the United States, Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. The INTERCEPT Red Blood Cell system is in clinical development. See http://www.cerus.com for information about Cerus.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

Forward Looking Statements

Except for the historical statements contained herein, this press release contains forward-looking statements concerning Cerus' anticipated business growth, anticipated product launches and other statements that are not historical facts. Actual results could differ materially from these forward-looking statements as a result of certain factors, including, without limitation, risks associated with: that Cerus may not grow sales in its U.S., EMEA and other major international markets; the uncertain and time-consuming development and regulatory process, including with respect to the label claims ultimately approved for INTERCEPT-treated red blood cells and cryoprecipitate; that Cerus may be unable to obtain CE Mark approval, or any other regulatory approvals, of the red blood cell system in a timely manner or at all; that Cerus may be unable to submit its planned PMA supplement to the FDA for INTERCEPT-treated cryoprecipitate from plasma on the anticipated timeframe or at all, and even if submitted, Cerus may be unable to obtain FDA approval, or any other regulatory approvals, of INTERCEPT-treated cryoprecipitate in a timely manner or at all; that applicable regulatory authorities may disagree with Cerus‘ interpretations of the data from its clinical studies and/or may otherwise determine not to approve Cerus' regulatory submissions in a timely manner or at all, as well as other risks detailed in Cerus' filings with the Securities and Exchange Commission, including Cerus' Quarterly Report on Form 10-Q for the quarter ended September 30, 2018, filed with the SEC on November 1, 2018. Cerus disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190104005102/en/